Abivax updates combination therapy strategy for ulcerative colitis with promising preclinical data on Obefazimod and Etrasimod.

Abivax has updated its strategy for a combination therapy program targeting ulcerative colitis (UC). The company announced early preclinical data demonstrating the effectiveness of its drugs, Obefazimod and Etrasimod, in a mouse model of inflammatory bowel disease (IBD). This research aims to advance treatment options for patients with UC.

September 25, 2024
12 Articles

Further Reading